Clinical correlates of low serum carnitine levels in hospitalized psychiatric patients

World Journal of Biological Psychiatry

Volumn 12, Issue 1, 2011, Pages 73-79

  Cuturic, Miroslav ^a   Abramson, Ruth K ^a   Moran, Robert R ^b   Hardin, James W ^b   Hall, Alicia V ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Carnitine; dementia; encephalopathy; psychiatry; valproic acid

Indexed keywords

BENZATROPINE; CARNITINE; CLONAZEPAM; LEVOTHYROXINE; OLANZAPINE; VALPROIC ACID;

ADULT; AGED; AGITATION; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CORRELATION ANALYSIS; DEMENTIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HOSPITAL PATIENT; HUMAN; MALE; MENTAL DISEASE; MENTAL PATIENT; METABOLIC ENCEPHALOPATHY;

ADULT; AGED; ANTIMANIC AGENTS; CARNITINE; FEMALE; HUMANS; INPATIENTS; MALE; MENTAL DISORDERS; MIDDLE AGED; POLYPHARMACY; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; VALPROIC ACID;

EID: 79551595148     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2010.489619     Document Type: Article

References (37)

1. Abdul HM, Butterfield DA. 2007. Involvement of PI3K/PKG/ERK1/2 signaling pathways in cortical neurons to trigger protection by cotreatment of acetyl-L-carnitine and alpha-lipoic acid against HNE-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. Free Radic Biol Med 42:371-384.
2. Angelini C, Vergani L, Martinuzzi A. 1992. Clinical and biochemical aspects of carnitine deficiency and insufficiency: transport defects and inborn errors of beta-oxidation. Crit Rev Clin Lab Sci. 29:217-242.
3. Binienda Z, Przybyla-Zawislak B, Virmani A, Schmued L. 2005. L-Carnitine and neuroprotection in the animal model of mitochondrial dysfunction. Ann NY Acad Sci 1053:174-182.
4. Breningstall GN. 1990. Carnitine deficiency syndromes. Pediatr Neurol 6:75-81.
5. Brenner RP. 1985. The electroencephalogram in altered states of consciousness. Neurol Clin 3:615-631.
6. Camiña MF, Rozas I, Castro-Gago M, Paz JM, Alonso C, Rodriguez-Segade S. 1991. Alteration of renal carnitine metabolism by anticonvulsant treatment. Neurology 41:1444-1448.
7. Crum RM, Anthony JC, Bassett SS, Folstein MF. 1993. Population-based norms for the Mini-Mental State Examination by age and educational level. J Am Med Assoc 269:2386-2391.
8. Dealberto MJ. 2007. Valproate-induced hyperammonaemic encephalopathy: review of 14 cases in the psychiatric setting. Int Clin Psychopharmacol 22:330-337.
9. Evans AM, Fornasini G. 2003. Pharmacokinetics of L-carnitine. Clin Pharmacokinet 42:941-967.
10. Filipek PA, Juranek J, Nguyen MT, Cummings C, Gargus JJ. 2004. Relative carnitine deficiency in autism. J Autism Dev Disord 34:615-623.
11. Folstein M, Folstein SE, McHugh PR. 1975. "Mini-Mental State "a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198.
12. Fouque D, Holt S, Guebre-Egziabher F, Nakamura K, Vianey-Saban C, Hadj-A ïssa A, et al. 2006. Relationship between serum carnitine, acylcarnitines, and renal function in patients with chronic renal disease. J Ren Nutr 16:125-131.
13. Galland S, Georges B, Le Borgne F, Conductier G, Dias JV, Demarquoy J. 2002. Thyroid hormone controls carnitine status through modifications of gamma-butyrobetaine hydroxylase activity and gene expression. Cell Mol Life Sci 59:540-545.
14. Guarnieri G, Biolo G, Toigo G, Situlin R. 2003. Carnitine in Renal Failure. In: Kopple DJ, Massry SG, eds. Kopple and Massry's nutritional management of renal disease. Philadelphia, Baltimore, New York, London, Buenos Aires, Hong Kong, Sydney, Tokyo: Lippincott Williams &Wilkins, a Wolters Kluwer Company. p. 357-369.
15. Hsu CC, Chuang YH, Tsai JL, Jong HJ, Shen YY, Huang HL et al. 1995. CPEO and carnitine deficiency overlapping in MELAS syndrome. Acta Neurol Scand 92:252-255.
16. Laub MC, Paetzkebrunner I, Jaeger G. 1986. Serum carnitine during valproic acid therapy. Epilepsia 27:559-562.
17. Lheureux PE, Penaloza A, Zahir S, Gris M. 2005. Science review: carnitine in the treatment of valproic acid-induced toxicity-what is the evidence? Crit Care 9:431-440.
18. Longo N, Amat di San Filippo C, Pasquali M. 2006. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet 142C:77-85.
19. Malaguarnera M, Cammalleri L, Gargante MP, Vacante M, Colonna V, Motta M. 2007. L-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial. Am J Clin Nutr 86:1738-1744.
20. Malaguarnera M, Gargante MP, Cristaldi E, Colonna V, Messano M, Koverech A, et al. 2008a. Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue. Arch Gerontol Geriatr 46:181-190.
21. Malaguarnera M, Gargante MP, Cristaldi E, Vacante M, Risino C, Cammalleri L, et al. 2008b. Acetyl-L-carnitine treatment in minimal hepatic encephalopathy. Dig Dis Sci 53:3018-3025.
22. Montgomery SA, Thal LJ, Amrein R. 2003. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int Clin Psychopharmacol 18:61-71.
23. Moreno FA, Macey H, Schreiber B. 2005. Carnitine levels in valproic acid-treated psychiatric patients: a cross-sectional study. J Clin Psychiatry 66:555-558.
24. Mynatt RL, Park EA, Thorngate FE, Das HK, Cook GA. 1994. Changes in carnitine palmitoyltransferase-I mRNA abundance produced by hyperthyroidism and hypothyroidism parallel changes in activity. Biochem Biophys Res Commun 201: 932-937.
25. National Academy of Sciences. 1996. Summary of WIC nutrition risk criteria: a scientific assessment. Committee on Scientific Evaluation of WIC Nutrition Risk Criteria Food and Nutrition Board, Institute of Medicine. J Am Diet Assoc 96:925-930.
26. Ohtani Y, Endo F, Matsuda I. 1982. Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J Pediatr 101:782-785.
27. Pistone G, Marino A, Leotta C, Dell'Arte S, Finocchiaro G, Malaguarnera M. 2003. Levocarnitine administration in elderly subjects with rapid muscle fatigue: effect on body composition, lipid profile and fatigue. Drugs Aging 20:761-767.
28. Pons R, De Vivo DC. 1995. Primary and secondary carnitine deficiency syndromes. J Child Neurol 10(Suppl 2):8-24.
29. Pueschel SM. 2006.The effect of acetyl-L-carnitine administration on persons with Down syndrome. Res Dev Disabil 27:599-604.
30. Rebouche CJ. 2004. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann NY Acad Sci 1033:30-41.
31. Scaglia F, Wang Y, Singh RH, Dembure PP, Pasquali M, Fernhoff PM, et al. 1998. Defective urinary carnitine transport in het-erozygotes for primary carnitine deficiency. Genet Med 1:34-39.
32. Sinclair C, Gilchrist JM, Hennessey JV, Kandula M. 2005. Muscle carnitine in hypo- and hyperthyroidism. Muscle Nerve 32:357-359.
33. Sztajnkrycer MD. 2002. Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol 40:789-801.
34. Takiyama N, Matsumoto K. 1998. Age-and sex-related differences of serum carnitine in a Japanese population. J Am Coll Nutr 17:71-74.
35. Tein I, Xie Z W. 1994. Reversal of valproic acid-associated impairment of carnitine uptake in cultured human skin fibroblasts. Biochem Biophys Res Commun 204:753-758.
36. Tolu P, Masi F, Leggio B, Scheggi S, Tagliamonte A, De Montis MG, et al. 2002. Effects of long-term acetyl-L-carnitine administration in rats: I. increased dopamine output in mesocorticolim-bic areas and protection toward acute stress exposure. Neuropsychopharmacology 27:410-420.
37. Urban TJ, Gallagher RC, Brown C, Castro RA, Lagpacan LL, Brett CM, et al. 2006. Functional genetic diversity in the high-affinity carnitine transporter OCTN2 (SLC22A5). Mol Pharmacol 70:1602-1611.